| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/02/2001 | WO2001055432A2 Polymorphisms in the human cyp2d6 gene promoter region and their use in diagnostic and therapeutic applications |
| 08/02/2001 | WO2001055396A1 NOVEL POLYPEPTIDES HmrA AND HmrB |
| 08/02/2001 | WO2001055393A2 Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1 |
| 08/02/2001 | WO2001055392A2 Nuclear hormone receptors |
| 08/02/2001 | WO2001055360A1 Slow release protein polymers |
| 08/02/2001 | WO2001055358A2 Phosphodiesterases |
| 08/02/2001 | WO2001055341A2 Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen |
| 08/02/2001 | WO2001055337A2 Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides |
| 08/02/2001 | WO2001055336A2 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 08/02/2001 | WO2001055210A2 Human cyr61 |
| 08/02/2001 | WO2001055178A2 Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer |
| 08/02/2001 | WO2001055148A1 Pyridopyrimidinone derivatives for treatment of neurodegenerative disease |
| 08/02/2001 | WO2001055108A2 Use of spl a2 inhibitors for the treatment of inflammation |
| 08/02/2001 | WO2001055103A2 Chimeric neuropeptide y receptors |
| 08/02/2001 | WO2001055092A2 5-aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents |
| 08/02/2001 | WO2001055086A1 Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity |
| 08/02/2001 | WO2001055085A1 Propionic acid derivatives and their use in the treatment of diabetes and obesity |
| 08/02/2001 | WO2001054771A2 Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor |
| 08/02/2001 | WO2001054742A1 A medicinal aerosol formulation |
| 08/02/2001 | WO2001054741A1 A medicinal aerosol formulation |
| 08/02/2001 | WO2001054729A1 Treatment of neuropsychiatric disease with protease and neuraminidase inhibitors |
| 08/02/2001 | WO2001054728A1 NOVEL REMEDIES WITH THE USE OF β3 AGONIST |
| 08/02/2001 | WO2001054725A1 Remedies and preventives for dental diseases |
| 08/02/2001 | WO2001054724A1 Anticancer compositions |
| 08/02/2001 | WO2001054723A1 Therapeutic method for reducing angiogenesis |
| 08/02/2001 | WO2001054722A1 Pre-transplant accommodated organs resistant to anti-donor immunity |
| 08/02/2001 | WO2001054721A1 Antagonist of th-1 immuneresponse inducing cytokine for the treatment of autoimmune diseases |
| 08/02/2001 | WO2001054711A2 Use of neurotoxins for treating diabetes |
| 08/02/2001 | WO2001054707A2 Modification of surface proteins by aminopeptidase inhibitors |
| 08/02/2001 | WO2001054703A1 Antifungal drug composition and drug delivery system |
| 08/02/2001 | WO2001054702A1 Novel compounds |
| 08/02/2001 | WO2001054699A1 Selective estrogen receptor modulators in combination with estrogens |
| 08/02/2001 | WO2001054694A1 Tetrahydropyrimidone inhibitors of fatty acid binding protein and method |
| 08/02/2001 | WO2001054686A2 L-arginine in combination with other compounds for treating cardiovascular diseases |
| 08/02/2001 | WO2001054685A1 Mucin synthesis inhibitors |
| 08/02/2001 | WO2001054683A1 Ibuprofen containing active agent preparation |
| 08/02/2001 | WO2001054681A2 Composition for treatment of stress |
| 08/02/2001 | WO2001054680A2 Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor |
| 08/02/2001 | WO2001054679A2 Transdermal composition containing an anesthetic and a vasodilator agent |
| 08/02/2001 | WO2001054678A2 Combination therapy for cancer |
| 08/02/2001 | WO2001054677A2 Ace inhibitor-vasopressin antagonist combinations |
| 08/02/2001 | WO2001054667A1 Electrospun pharmaceutical compositions |
| 08/02/2001 | WO2001054659A2 Slimming cosmetic composition comprising a plant extract containing a plant natriuretic peptide (pnp) |
| 08/02/2001 | WO2001054652A2 A method of inducing autovaccination against hiv infection using structured treatment interruptions |
| 08/02/2001 | WO2001015547A3 Active agent preparation for veterinary use and method for the production thereof |
| 08/02/2001 | WO2001014584A3 Methods of identifying anti-viral agents |
| 08/02/2001 | WO2001014548A3 New g-protein coupled receptor and dna sequences thereof |
| 08/02/2001 | WO2001013932A3 Stimulation of sperm function |
| 08/02/2001 | WO2001012189A8 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 08/02/2001 | WO2001004305A3 Human proteins involved in detoxification |
| 08/02/2001 | WO2001001969A3 Methods of treating and/or suppressing weight gain |
| 08/02/2001 | WO2001000828A3 Compositions and methods for the therapy and diagnosis of lung cancer |
| 08/02/2001 | WO2001000189A3 Combination of mtp inhibitors and active agents that influence the metabolism and use thereof in medicaments |
| 08/02/2001 | WO2000070036A3 Genes expressed in hippocampus |
| 08/02/2001 | WO2000069898A3 Molecular interactions in allergy cells |
| 08/02/2001 | WO2000069887A3 Rapid dehydration of proteins |
| 08/02/2001 | WO2000067847A3 Use of dopamine d3 receptor ligands for producing medicaments for treating kidney disorders |
| 08/02/2001 | WO2000066175A3 Conjugates as therapies for cancer and prostate diseases |
| 08/02/2001 | WO2000051589A9 VACUOLAR-TYPE (H+)-ATPase-INHIBITING COMPOUNDS, COMPOSITIONS, AND USES THEREOF |
| 08/02/2001 | WO2000047625A3 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith |
| 08/02/2001 | WO2000046391A9 Genes displaying enhanced expression during cellular senescence and terminal cell differentiation and uses thereof |
| 08/02/2001 | WO1999066918A8 Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
| 08/02/2001 | US20010011127 Modulating activity of endogenous protein |
| 08/02/2001 | US20010011124 Genetic engineering |
| 08/02/2001 | US20010011098 Pharmaceutical composition for angiotensin II-mediated diseases |
| 08/02/2001 | US20010011097 Methods and compositions for treating and preventing mucositis |
| 08/02/2001 | US20010011092 High affinity ligands for nociceptin receptor ORL-1 |
| 08/02/2001 | US20010011083 Pain reliever and method of use |
| 08/02/2001 | US20010011082 Mixture with chelate compound; bone disorders |
| 08/02/2001 | US20010011080 Composition containing sucrafate and a topical anesthetic for humans and animals and method of use thereof |
| 08/02/2001 | US20010011077 Secreted cysteine rich protein-6 (SCRP-6); polynucleotides and processes for producing polypeptides |
| 08/02/2001 | US20010011072 Skin disorders; kidney and liver disorders |
| 08/02/2001 | US20010010929 Polynucleotides and polypeptides belonging to the uncoupling proteins family |
| 08/02/2001 | US20010010921 Cell-free and cell-based assays for screening drugs to treat eating disorders; dietetics; obesity, cachexia |
| 08/02/2001 | US20010010913 Isolated polypeptide |
| 08/02/2001 | US20010010825 Rapidly disintegrable solid preparation |
| 08/02/2001 | DE10011926A1 Genetisch veränderte Fibroblastenzellen Genetically modified fibroblast cells |
| 08/02/2001 | DE10003757A1 Ibuprofen-Wirkstoffzubereitung Ibuprofen drug preparation |
| 08/02/2001 | DE10003620A1 Non-aqueous solution or suspension of 5-aminolevulinic acid, is useful in the treatment or diagnosis of tumor diseases or psoriasis by photodynamic therapy |
| 08/02/2001 | CA2401086A1 Antagonist of th-1 immuneresponse inducing cytokine for the treatment of autoimmune diseases |
| 08/02/2001 | CA2398821A1 Composition for treatment of stress |
| 08/02/2001 | CA2398788A1 Slow release protein polymers |
| 08/02/2001 | CA2398756A1 Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen |
| 08/02/2001 | CA2398743A1 Novel mhc class ii restricted t cell epitopes from the cancer antigen, ny eso-1 |
| 08/02/2001 | CA2398660A1 Human cyr61 |
| 08/02/2001 | CA2398643A1 Novel compounds |
| 08/02/2001 | CA2398642A1 Mucin synthesis inhibitors |
| 08/02/2001 | CA2398631A1 Slimming cosmetic composition comprising as an ative agent a plant extract containing a plant natriuretic peptide (pnp) |
| 08/02/2001 | CA2398564A1 Nuclear hormone receptors |
| 08/02/2001 | CA2398548A1 Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides |
| 08/02/2001 | CA2398546A1 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 08/02/2001 | CA2398503A1 Therapeutic method for reducing angiogenesis |
| 08/02/2001 | CA2398358A1 The neurosteroid dhea as a marker for neuropathologies |
| 08/02/2001 | CA2398288A1 Ibuprofen containing active agent preparation |
| 08/02/2001 | CA2398199A1 Novel therapeutic agents that use a .beta.3 agonist |
| 08/02/2001 | CA2398104A1 Polymorphisms in the human cyp2d6 gene promoter region and their use in diagnostic and therapeutic applications |
| 08/02/2001 | CA2398003A1 Phosphodiesterases |
| 08/02/2001 | CA2397991A1 Diagnosis of tauopathies determining tau/phospho-tau ratio |
| 08/02/2001 | CA2397523A1 Combination therapy for cancer |
| 08/02/2001 | CA2396640A1 Electrospun pharmaceutical compositions |